News
Lilly inflates US facility investment spending by $4.5bn
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Market Access
Anglonordic Life Science 2026: A focus on execution
The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
News
Pfizer, Arvinas join SERD club with Veppanu approval
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News
Danco fights back after US court curbs abortion pill access
In another setback for abortion care in the US, an appeals court has issued an order restricting the distribution of mifepristone through the mail.
News
FDA's ODAC delivers one loss, one win for AstraZeneca
The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
